Ocular lymphoproliferative disorders.
Journal
Current opinion in ophthalmology
ISSN: 1531-7021
Titre abrégé: Curr Opin Ophthalmol
Pays: United States
ID NLM: 9011108
Informations de publication
Date de publication:
01 Nov 2021
01 Nov 2021
Historique:
pubmed:
20
8
2021
medline:
16
10
2021
entrez:
19
8
2021
Statut:
ppublish
Résumé
Ocular lymphoproliferative disorders are a heterogenous group of pathologic disorders with significant impact on quality of life and, at times, may be life-threatening. Due to the rarity of these disorders, information regarding proper diagnosis, treatment, and prognosis is limited. This review summarizes the key features of the unique diseases within this group of lymphoproliferative disorders, with a focus on disease presentation, diagnostic considerations, and treatment and prognosis. High-quality data from recent studies have provided answers regarding clinical outcomes for subsets of ocular lymphoproliferative disorders and are included herein. New diagnostic techniques are also discussed as well as current treatment strategies. Ocular lymphoproliferative disorders are a rare group of diseases. Key features of each disease is presented in this review in a concise and readable format, as well as updated information regarding diagnostic considerations and treatment options.
Identifiants
pubmed: 34411030
doi: 10.1097/ICU.0000000000000796
pii: 00055735-202111000-00008
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
541-548Informations de copyright
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.
Références
Andrew NH, Coupland SE, Pirbhai A, Selva D. Lymphoid hyperplasia of the orbit and ocular adnexa: a clinical pathologic review. Surv Ophthalmol 2016; 61:778–790.
Korn BS, Burkat CN, Carter KD, et al. Oculofacial plastic and orbital surgery. 2020; San Francisco: American Academy of Ophthalmology, (Basic and Clinical Science Course).
Yen MT, Bilyk JR, Wladis EJ, et al. Treatments for ocular adnexal lymphoma: a report by the American Academy of Ophthalmology. Ophthalmology 2018; 125:127–136.
Cockerham GC, Jakobiec FA. Lymphoproliferative disorders of the ocular adnexa. Int Ophthalmol Clin 1997; 37:39–59.
Olsen TG, Holm F, Mikkelsen LH, et al. Orbital lymphoma-an international multicenter retrospective study. Am J Ophthalmol 2019; 199:44–57.
Chang TS, Byrne SF, Gass JD, et al. Echographic findings in benign reactive lymphoid hyperplasia of the choroid. Arch Ophthalmol 1996; 114:669–675.
Venkateswaran N, Mercado C, Tran AQ, et al. The use of high resolution anterior segment optical coherence tomography for the characterization of conjunctival lymphoma, conjunctival amyloidosis and benign reactive lymphoid hyperplasia. Eye Vis (Lond) 2019; 6:17.
AlAkeely AG, Alkatan HM, Alsuhaibani AH, et al. Benign reactive lymphoid hyperplasia of the conjunctiva in childhood. Br J Ophthalmol 2017; 101:933–939.
Kang HM, Kang EM, Lee SC. A Korean woman with reactive lymphoid hyperplasia of the uvea. Korean J Ophthalmol 2014; 28:354–355.
Grossniklaus HE, Martin DF, Avery R, et al. Uveal lymphoid infiltration. Report of four cases and clinicopathologic review. Ophthalmology 1998; 105:1265–1273.
Aronow ME, Portell CA, Sweetenham JW, Singh AD. Uveal lymphoma: clinical features, diagnostic studies, treatment selection, and outcomes. Ophthalmology 2014; 121:334–341.
Cockerham GC, Hidayat AA, Bijwaard KE, Sheng ZM. Re-evaluation of ‘reactive lymphoid hyperplasia of the uvea’: an immunohistochemical and molecular analysis of 10 cases. Ophthalmology 2000; 107:151–158.
Shields CL, Arepalli S, Pellegrini M, et al. Choroidal lymphoma shows calm, rippled, or undulating topography on enhanced depth imaging optical coherence tomography in 14 eyes. Retina 2014; 34:1347–1353.
Aronow ME, Portell CA, Rybicki LA, et al. Ocular adnexal lymphoma: assessment of a tumor-node-metastasis staging system. Ophthalmology 2013; 120:1915–1919.
Mashayekhi A, Shukla SY, Shields JA, Shields CL. Choroidal lymphoma: clinical features and association with systemic lymphoma. Ophthalmology 2014; 121:342–351.
Kam AW, Galvin J, Cherepanoff S, et al. Primary choroidal lymphoma diagnosed with 27-gauge pars plana vitrectomy choroidal biopsy. Case Rep Ophthalmol 2019; 10:213–220.
Hernández-Pons A, Gómez-Beltrán E, Fernández-Zarzoso M, et al. Choroidal lymphoma diagnosed by polymerase chain reaction-based clonality assessment. Eur J Ophthalmol 2021; 31:N97–101.
Yang X, Dalvin LA, Lim LS, et al. Ultra-low-dose (boom-boom) radiotherapy for choroidal lymphoma in three consecutive cases. Eur J Ophthalmol 2021; 31:N91–N96.
Chan C-C, Rubenstein JL, Coupland SE, et al. Primary vitreoretinal lymphoma: a report from an International Primary Central Nervous System Lymphoma Collaborative Group symposium. Oncologist 2011; 16:1589–1599.
AlQahtani A, Touitou V, Cassoux N, et al. More than a masquerade syndrome: atypical presentations of vitreoretinal lymphomas. Ocul Immunol Inflamm 2014; 22:189–196.
Levy-Clarke GA, Chan C-C, Nussenblatt RB. Diagnosis and management of primary intraocular lymphoma. Hematol Oncol Clin North Am 2005; 19:739–749. viii.
Fardeau C, Lee CPL, Merle-Béral H, et al. Retinal fluorescein, indocyanine green angiography, and optic coherence tomography in non-Hodgkin primary intraocular lymphoma. Am J Ophthalmol 2009; 147:886.e1–894.e1.
Velez G, Chan C-C, Csaky KG. Fluorescein angiographic findings in primary intraocular lymphoma. Retina 2002; 22:37–43.
Deák GG, Goldstein DA, Zhou M, et al. Vertical hyperreflective lesions on optical coherence tomography in vitreoretinal lymphoma. JAMA Ophthalmol 2019; 137:194–198.
Davis JL, Miller DM, Ruiz P. Diagnostic testing of vitrectomy specimens. Am J Ophthalmol 2005; 140:822–829.
Whitcup SM, Stark-Vancs V, Wittes RE, et al. Association of interleukin 10 in the vitreous and cerebrospinal fluid and primary central nervous system lymphoma. Arch Ophthalmol 1997; 115:1157–1160.
Kuiper J, Ten Dam-van Loon N, Domanian A, et al. Correlation between measurement of IL-10 and IL-6 in paired aqueous humour and vitreous fluid in primary vitreoretinal lymphoma. Acta Ophthalmol 2015; 93:e680–e681.
Frenkel S, Pe’er J, Kaufman R, et al. The importance of cytokines analysis in the diagnosis of vitreoretinal lymphoma. Acta Ophthalmol 2020; 98:e668–e673.
Raja H, Salomão DR, Viswanatha DS, Pulido JS. Prevalence of MYD88 L265P mutation in histologically proven, diffuse large B-cell vitreoretinal lymphoma. Retina 2016; 36:624–628.
Frenkel S, Hendler K, Siegal T, et al. Intravitreal methotrexate for treating vitreoretinal lymphoma: 10 years of experience. Br J Ophthalmol 2008; 92:383–388.
Larkin KL, Saboo US, Comer GM, et al. Use of intravitreal rituximab for treatment of vitreoretinal lymphoma. Br J Ophthalmol 2014; 98:99–103.
de la Fuente MI, Alderuccio JP, Reis IM, et al. Bilateral radiation therapy followed by methotrexate-based chemotherapy for primary vitreoretinal lymphoma. Am J Hematol 2019; 94:455–460.
Dalvin LA, Lim LS, Ancona-Lezama D, et al. Clinical features predictive of survival in patients with vitreoretinal lymphoma: analysis of 70 patients at a single ocular oncology center. Asia Pac J Ophthalmol (Phila) 2020; 9:110–116.
Grimm SA, Pulido JS, Jahnke K, et al. Primary intraocular lymphoma: an International Primary Central Nervous System Lymphoma Collaborative Group Report. Ann Oncol 2007; 18:1851–1855.
Riemens A, Bromberg J, Touitou V, et al. Treatment strategies in primary vitreoretinal lymphoma: a 17-center European collaborative study. JAMA Ophthalmol 2015; 133:191–197.